BTIG has increased its 12-month price target for CareDx to $92 from $81, maintaining a 'Buy' rating, following the company's third-quarter financial results. This adjustment reflects a 13.6% increase in the target price and an implied upside of 28.6% from the previous closing price, aligning with a broader positive shift in analyst consensus.
BTIG raised its price target for CareDx (CDNA) to $92 from $81, while reiterating its 'Buy' rating, following the company's Q3 financial results. This move signals increased analyst confidence in CareDx's future performance, as evidenced by the 13.6% target price increase and a 28.6% implied upside. This positive re-rating, alongside a rising average analyst price target, could attract more investor interest in the short term, potentially leading to upward price momentum for CDNA. For traders, this presents an opportunity to capitalize on positive sentiment and potential price appreciation, though long-term implications will depend on the company's ability to meet or exceed these elevated expectations.